Cannabis in Portugal 2026: Decriminalisation, Lei 30/2000 and What It Really Means

1. The Portuguese Model: Why It Was Revolutionary

To understand the real impact of what Portugal did in 2000, you need to put it in context: Europe was living through the peak of the heroin epidemic. In Portugal, it was estimated that more than 1% of the total population was heroin-dependent, a figure without parallel in the EU. Prisons were overflowing with users. Hospitals could not cope. HIV was spreading through shared needles at the speed of a humanitarian catastrophe.

The government of António Guterres commissioned the most honest possible analysis of the situation from a technical committee chaired by jurist João Goulão. The conclusion was unequivocal: criminalising consumers did not reduce consumption, it only drove them underground and prevented them from accessing treatment. The drug problem in Portugal was not a security problem. It was a public health problem.

On 29 November 2000, the Portuguese Parliament passed Lei 30/2000. It entered into force on 1 July 2001. It was the first legislation of its kind in the entire European Union: the possession and use of any drug, in quantities considered for personal use, was no longer a criminal offence but an administrative infraction of a health nature.

What nobody expected to happen

Critics predicted exactly what they always predict: that Portugal would become a drug tourism destination for addicts from across Europe, that consumption would spike among young people, that society would fall apart. None of the three things happened.

What did happen was meticulously documented over more than two decades by the Instituto da Droga e da Toxicodependência (IDT) and by independent researchers such as those at the Cato Institute, whose 2009 report was the first rigorous external analysis to confirm the model's success. Drug use did not spike. HIV cases related to intravenous drug use plummeted. Fatal overdoses decreased. And Portugal began receiving visits from government delegations from around the world wanting to understand how they had done it.

The key was something Portugal understood before anyone else: decriminalisation alone is not enough. It only works if accompanied by real investment in treatment, harm reduction and social reintegration. The money previously spent on judicially processing consumers was redirected to health programmes. That is the real secret of the Portuguese model.

2. Decriminalisation vs Legalisation: The Crucial Difference

The most common mistake when talking about the Portuguese model is confusing decriminalisation with legalisation. These are two radically different concepts, and the confusion has very serious practical consequences for anyone travelling to Portugal thinking they can freely buy cannabis in a shop.

The most important distinction to internalise: there is no legal cannabis recreational market in Portugal. There are no cannabis shops, no coffee shops, no dispensaries. You cannot buy cannabis legally in any establishment. The cannabis that someone consumes in Portugal has passed through the black market, just as in Spain or any other European country where it is not legalised.

What changes is what happens after the police find you with that quantity. And that is where Portugal is radically different.

3. The 10-Day Threshold: How the Limits Are Calculated

Portaria 94/96 established the threshold system still in force today. The logic is apparently simple: if a person has a quantity corresponding to 10 days of personal use, it is assumed to be for their own use. If they have more, the presumption of trafficking comes into play.

For cannabis herb, the reference daily dose established is 2.5 grams per day. Multiplied by 10, you get the 25 gram threshold. For hashish, the reference daily dose is 0.5 grams, giving the 5 gram threshold. These quantities are higher than those of many neighbouring countries, reflecting the public health philosophy underlying the model.

Since the passage of Lei 55/2023 in August 2023, a change of enormous practical legal importance occurred: the burden of proof was reversed. Before this law, if a person was found with a quantity above the threshold, the burden fell on them to demonstrate it was for personal use. It was enormously difficult to prove. Now it is the State that must demonstrate that the intent is distribution. A technical change with very significant real consequences for those intercepted with borderline quantities.

Substance	Reference daily dose	Threshold (10 days)	Above threshold
Cannabis herb	2.5 g/day	25 grams	Presumption of trafficking
Hashish	0.5 g/day	5 grams	Presumption of trafficking
Heroin	0.1 g/day	1 gram	Presumption of trafficking
Cocaine	0.2 g/day	2 grams	Presumption of trafficking
MDMA / Ecstasy	0.5 tablets/day	5 tablets	Presumption of trafficking
Amphetamines	0.2 g/day	2 grams	Presumption of trafficking
LSD	0.5 doses/day	5 doses	Presumption of trafficking
Methamphetamine	0.1 g/day	1 gram	Presumption of trafficking

It is essential to understand that these thresholds are not thresholds of total impunity. Being below the threshold does not mean nothing happens. It means the process that follows is administrative and health-related, not criminal. That is the whole difference, but it is an enormous difference.

4. The CDTs: How the Process Works If You Get Caught

If the Polícia de Segurança Pública (PSP) or Guarda Nacional Republicana (GNR) intercepts you with a quantity equal to or below the threshold, they will not detain you. You will not go to a police station under arrest. There will be no criminal charges. You will have no criminal record. What will happen is that a record of the seized substance will be made and you will receive a summons to appear before the CDT in your district.

What the CDTs are

The Comissões para a Dissuasão da Toxicodependência are administrative, not judicial, bodies. There are 18 commissions distributed throughout the Portuguese territory. Each CDT is made up of three members: a lawyer who serves as president, a doctor and a social worker. This composition is not accidental: it reflects the tripartite approach of the Portuguese model, which addresses addiction from the legal, medical and social perspective simultaneously.

The process step by step

The appearance before the CDT is an informal hearing, not a trial. The panel listens to the person, evaluates their situation and classifies the case into one of two fundamental categories: occasional or non-dependent user, or user with dependency. And that is where the paths diverge.

For the vast majority of cases — more than 90% according to IDT records — these are non-dependent people. In these cases, the CDT can make several decisions:

• Suspension of proceedings: the sanction is provisionally suspended, generally with conditions (no reoffending during a set period). This is the most common outcome.
• Formal warning: an official reprimand with no criminal or financial consequences.
• Administrative sanction: may include a fine, prohibition from exercising certain professions or activities, or suspension of certain civil rights. Only in a minority of cases.
• Community service: instead of a financial fine.

For those showing signs of dependency, the CDT can refer them to treatment. And here is the key point: treatment is always voluntary. The CDT can recommend and offer it, but cannot force anyone to follow it. If the person accepts treatment, the sanction is suspended while the therapeutic process lasts.

Only about ~10% of cases going through the CDTs end in an effective sanction. The rest are resolved through provisional suspension, voluntary referral to social services or closure of the case. In practical terms, for a tourist or foreign visitor found with less than 25 grams of cannabis, the most likely outcome is an uncomfortable appearance before a three-person panel and a summons to a hearing that will probably conclude without lasting consequences.

5. Medical Cannabis: The Unfulfilled Promise

In July 2018, Portugal took its second major legislative step on cannabis: Lei 33/2018, complemented by Decreto-Lei 8/2019, legalised the use of cannabis for therapeutic purposes. On paper, it was a significant advance. In practice, the gap between what the law promised and what has happened is enormous.

The seven official indications

Medical cannabis in Portugal is authorised exclusively for the following therapeutic indications, validated by INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde):

• Epilepsy refractory to other treatments
• Chronic pain not responding to conventional therapy
• Nausea and vomiting associated with chemotherapy
• Spasticity in multiple sclerosis
• Anorexia and weight loss in HIV/AIDS patients
• Post-Traumatic Stress Disorder (PTSD)
• Alzheimer's disease

The numbers that evidence the practical failure

The most revealing data on the state of medical cannabis in Portugal is this: during all of 2023, INFARMED recorded only 1,157 prescriptions of medical cannabis across the entire country. For a country of 10 million inhabitants, with seven approved indications affecting hundreds of thousands of patients, that figure is devastatingly low.

Why so few prescriptions? The reasons accumulate. First, no medical cannabis product is covered by the SNS, the public health system. The patient pays entirely out of pocket, and prices are high. Second, only a specialist — not a GP — can prescribe, creating an enormous access barrier for patients who already struggle to reach specialists. Third, many doctors still have cultural and training resistance to prescribing cannabis.

Available products

Products authorised by INFARMED for pharmacy dispensing include mainly Bedrocan varieties (Dutch): Bedrocan, Bediol and Bedrolite, as well as Tilray and Noidecs products. These are standardised products with precise THC and CBD contents, grown under certified pharmaceutical conditions. The problem is not product quality. The problem is access.

The contrast with countries like Germany — where medical cannabis is covered by insurers and accessible with a general prescription — or the Netherlands itself, makes the Portuguese system look like a half-baked reform. The legal infrastructure exists. Real accessibility for the average patient, does not.

6. CBD and HHC in 2026: What Is Now Prohibited

CBD: illegal according to INFARMED

INFARMED Circular 014/2022 was clear and unequivocal: cannabidiol (CBD) is considered an unauthorised medicinal product in Portugal. This means its sale, distribution and commercialisation is illegal under Portuguese pharmaceutical law, regardless of the product's THC content.

This position contrasts markedly with that of other EU countries that have interpreted CBD as a dietary supplement or cosmetic under certain conditions. In Portugal, INFARMED has not adopted that interpretation. The practical result is that CBD shops that proliferated between 2019 and 2022 have received sanctions, their products have in some cases been seized, and the market has entered a zone of considerable uncertainty.

However, a caveat: sanctions have not been uniform or systematic. Many establishments continue to operate in a de facto grey area, waiting for the regulatory position to evolve. But anyone travelling to Portugal assuming they can freely buy CBD as in Spain or Germany may be in for an unpleasant surprise.

HHC and derivatives: express prohibition since May 2026

On 8 May 2026, Portugal passed Lei 19-F/2026, becoming one of the first EU countries to legislate specifically against semi-synthetic cannabinoids with its own law. The regulation expressly prohibits:

• HHC (hexahydrocannabinol)
• HHCP (hexahydrocannabiphorol)
• HHC-O (hexahydrocannabinol acetate)
• Any derivative or analogue of these compounds

The prohibition is total: production, importation, exportation, commercialisation and possession with intent to distribute. For personal possession, the same mechanisms of Lei 30/2000 will apply — i.e., CDT process instead of criminal process — but HHC possession is no longer a grey area.

This law came in response to the expansion of the HHC market in Portugal, especially in Lisbon, where the product was sold openly in herbal shops and supplement stores as a legal alternative to THC. That legal gap no longer exists.

7. Will Legalisation Come? The Political Debate in 2026

The question the entire cannabis community in Portugal has been asking for years is whether the country that was first to decriminalise all drugs will also be first in the EU to legalise recreational cannabis for adults. In May 2024, the question moved from theory to parliament.

Projeto de Lei 89/XVI

PL 89/XVI, presented by Bloco de Esquerda (Portuguese alternative left) in May 2024, proposes creating a regulated cannabis market for adults in Portugal. The main elements of the proposal are:

• Legal sale in authorised establishments to those aged 18 and over
• Licensing system with fees and product regulation
• Domestic production under state supervision
• Reinvestment of tax revenues in health and prevention programmes
• Personal cultivation permitted (limited number of plants)
• Advertising ban and sales space restrictions

At the time of publication of this article (July 2026), PL 89/XVI remains in parliamentary proceedings without a definitive vote having taken place. The centre-right PSD government that won the March 2024 elections has not shown enthusiasm for the proposal. The coalition needed to pass it in Parliament is uncertain.

The arguments in the debate

Supporters of legalisation point out that Portugal has already demonstrated it can be a pioneer in drug policy and come out winning. They argue that the black cannabis market remains intact after 25 years of decriminalisation — because decriminalisation does not affect supply, only demand — and that market regulation would allow quality control, generate tax revenue and eliminate organised crime from the business.

Critics, mainly from the conservative wing, point out that Portugal is a pioneer in decriminalising consumption, not production and sale, and that taking that step would be a qualitatively different change. There is also discussion about the obligations of UN international drug treaties, although Germany showed in 2024 that it is possible to advance without formally withdrawing from the treaties.

The debate is alive. Polls show most Portuguese support some form of cannabis regulation. Urban young people are largely in favour. Rural areas and the conservative electoral base, more reluctant. The outcome of PL 89/XVI will ultimately depend on the parliamentary geometry of the coming years.

8. 25 Years on a Timeline

9. The Statistical Legacy: 25 Years of Data That Speak

Twenty-five years is enough for the data to be conclusive. And the Portuguese data constitutes the strongest argument in favour of harm reduction policies over criminal repression. We analyse the most relevant metrics.

The argument that dismantles the myth

The data showing 2.4% cannabis use prevalence among Portuguese adults versus the 8% EU average deserves careful reflection. Portugal, the most permissive country for drug use in the entire EU, has one of the lowest cannabis consumption rates on the continent.

This does not mean decriminalisation caused that low consumption — there are cultural, economic and social factors that also play a role — but it definitively dismantles the central argument of those opposing permissive policies: that relaxing drug laws necessarily leads to greater consumption. The 25 years of Portuguese data show there is no such direct causal relationship.

What there is is a clear correlation between harm reduction policies — access to clean needles, supervised consumption rooms, substitution treatment like methadone — and a reduction in the most serious harms associated with problematic use: HIV, hepatitis, fatal overdoses. Portugal invested in public health and public health outcomes improved. The logic is that direct.

10. Comparison: Portugal vs Spain vs Rest of EU

To place the Portuguese model in the European context, comparing with Spain — our neighbour with whom we share so many cultural and social similarities — and with the most relevant other countries is particularly illustrative.

Country	Personal possession	Cultivation	Medical cannabis	CBD	Adult use
Portugal	Decriminalised (≤25g)	Illegal	Legal (pharmacies, no SNS)	Illegal (INFARMED)	2.4%
Spain	Decriminalised (private use)	Cannabis clubs (grey area)	Legal (pharmacies + AEMPS)	Grey area (cosmetics/flowers)	9.4%
Germany	Legalised (CanG 2024, ≤25g)	Up to 3 plants adults	Legal + covered by insurance	Legal (food + cosmetics)	8.5%
Netherlands	Tolerated (≤5g)	Up to 5 plants tolerated	Legal + partially covered	Legal	14.3%
France	Illegal (flat fine €200)	Illegal	Experimental authorisation	Legal (flowers included)	11.1%
Italy	Partial decriminalisation	Illegal	Legal (pharmacies)	Legal (≤0.2% THC)	9.9%
EU average	Variable	Mostly illegal	Legal in majority of MSs	Variable	~8%

The table reveals an interesting paradox: Spain, with a formally more restrictive system than Portugal on paper but with greater practical tolerance (cannabis clubs, private space consumption with no real consequences), has almost four times Portugal's consumption rate. Germany, which legalised in 2024, is above Portugal. The Netherlands, with its coffee shops, has the highest consumption in the table.

What this suggests is that the determinants of cannabis use are complex and multifactorial, and that legal policy is only one of them. To continue exploring the situation in other countries, read our analysis of the cannabis legal map in Europe 2026 and the specific analysis of legalisation in Germany and the CanG 2024.

Frequently Asked Questions